Loading...

AUROPHARMA Aurobindo Pharma Ltd Quarterly Earnings Reports Announcement

rbnd

RPHR

Aurobindo Pharma Ltd

(AUROPHARMA)

2025 Announcement

Inspection Outcome

Share transfer window

Transfer to IEPF

US FDA Inspection

Investor Meeting

FDA Inspection Closure

Q2 FY26 transcript

Financial Results Published

Q2 Financial Results

Investor Presentation

Financial Results Q2

Management Change

Volume Movement Clarification

Investor Plant Visit

Earnings Call Date

New Subsidiary Launch

Share Transfer Window

Compliance Certification

Management Change

Share Transfer Complete

Share Transfer Update

Stake Acquisition Update

Fire Incident Report

Successful Phase 3 Study

New Subsidiary Launch

Volume Clarification

FDA Inspection Completed

Share Transfer Notice

FDA Inspection Complete

Share Transfer Update

Investor Meeting

Investor Meeting

Biosimilar Approval

Newspaper Publication

Shareholder Notification

Annual General Meeting

Investor Meeting

Earnings Call Transcript

Financial Results Published

Q1 FY26 Results

Investor Presentation

Media Clarification

Aurobindo Acquisition

Share Acquisition

Earnings Call Announcement

Special Window Notice

Compliance Certificate

Subsidiary Merger

Biosimilar Approval

Stake Acquisition Update

Production Restart

Biosimilar Approval

Investor Meeting

Investor Meeting

Investor Meeting

New Subsidiary Formed

Investor Meeting

Investor Meeting

Customs Duty Order

Earnings Call Transcript

Investor Meeting

New Subsidiary Established

Financial Results Published

Safety Incident Update

Secretarial Auditor Appoint...

Investor Presentation

Financial Results

Earnings Call Schedule

Annual Compliance Report

Zefylti Approval

GST Order Notice

Safety Incident

Positive CHMP Opinion

Product Approval

FDA Inspection Completed

Biosimilar Study Success

Marketing Authorization Gra...

Compliance Certificate

Cautionary Email

Cautionary Notice

Acquisition Update

Share Allotment

FDA Inspection Result

Investor Plant Visit

Investor Conference

License Agreement Termination

Investor Meeting

Tax Order Received

Acquisition Completed

Investor Plant Visit

FDA Inspection Update

Investor Meeting Notice

FDA Inspection Completed

Investor Plant Visit

Investor Plant Visit

Postal Ballot Notice

Zefylti® Approval

Q3 FY25 Earnings Call

Financial Results Publication

Director Re-appointment

Stake Acquisition

Investor Presentation

Q3 Financial Results

Aquisition of Tergene

GST Demand Order

Investor Meet Scheduled

Investor Meet Scheduled

Positive Opinion Received

Tax Recovery Orders

Earnings Call Scheduled

US FDA EIR Received

Compliance Certificate

NSE Warning Letter

Biosimilar Approval

FDA Inspection Completed

Regulatory Order Received

Biosimilar Approval

Director Retirement

Equity Share Allotment

Company Clarification

Investor Meeting

New Collaboration Agreement

Equity Share Transfer

Investor Meeting Notice

Earnings Call Transcript

Investor Meeting

GMP Certification Granted

Earnings Call Recording

Financial Results Released

Financial Results Correction

Investor Presentation

Financial Results Q2FY25

Investor Meeting

Earnings Call Schedule

New Facility Inauguration

Subsidiary Acquisition

Securities Update

Stake Sale Completed

FDA Inspection Completion

Investor Meeting

GLS Acquisition

FDA Inspection Report

Share Transfer Notice

FDA Approval Received

GST Demand Order

Investor Meetings

Buyback Completion

Buyback Announcement

Q1 FY25 Earnings Call

FDA Warning Letter

Investor Meeting

Investor Meeting

Earnings Call Audio

Financial Results Published

Investor Presentation

Strong Q1 Results

Newspaper Advertisement

FDA Inspection Status

Buyback Announcement

Buyback Announcement

Certificate Submission

Acquisition Announcement

US FDA Inspection

Investor Meeting Participation

Investor Meeting

Investor Meeting

Investor Meeting

Investor Meet Participation

Investor Meeting

Investor Meet Participation

Publication of Financial Re...

Investor Presentation

Financial Results

Reappointment of Directors

US FDA Inspection Classific...

Investor Meeting Intimation

Compliance Submission

Scheme of Amalgamation

FDA Inspection Completion

Statutory Order received

Acquisition Announcement

Completion of Disposal

Investor Meeting

Investor Meeting

Accident in Unit 6

Management Change

Completion of US FDA Inspec...

Compliance Certificate

Compliance Certificate

Postal Ballot Notice

Certificate submission

Commercial Production Comme...

Agreement Extension

Directorate Change

Newspaper Publication

Major Product Launch

Investor Presentation

Restarting Distribution

Compliance Accepted

Investor Media Meeting

Investor Meeting Update

Management Change

Production Restart

US FDA Inspection Completion

Investor Meet Intimation

Investor Meet Participation

Participation in Investor /...

Publication Notice

US FDA Inspection

USFDA Approval for Deflazac...

Audio Recording Uploaded

Newspaper Publication

Financial Results Announcement

Earnings Presentation

Change in Directorate

Regulatory Action

Investor/Analyst Meet

Participation in Investor /...

Investor/Analyst meet

Disposal of Business Assets

FDA Inspection Completion

FDA Inspection Update

US FDA Inspection

Certificate Submission

USFDA Approval for Posacona...

Completion of Inspection

US FDA Inspection

Investor/Analyst Meet

Acquisition Completion

Investor Meeting

Participation in Investor /...

Pharma Approval

USFDA Approval for Darunavi...

Notice published in newspap...

Incorporation of new subsid...

Acquisition Completed

Completion Of Purchase

FDA Approval of Ryzneuta fo...

Completion of FDA Inspectio...

Investor Meeting

Resignation of Independent ...

Investor/Analyst Meetings

Publication of Financial Re...

Recording Uploaded

Investor Presentation

Financial Results Announcement

Appointment of a Director

Acquisition of Theranym Bio...

Investor Conferences

USFDA Approval for Testoste...

Inauguration of manufacturi...

Contract Manufacturing Oper...

Compliance Certificate

Response to Clarification

Sale and Transfer of API Units

Completion of US FDA Inspec...

License Agreement with Hill...

Investor / Analyst meet

Completion of Inspection at...

Newspaper Publication

Acquisition of Marketing an...

US FDA Inspection Classific...

News Clarification

Merger or Acquisition Annou...

Financial Statements

Financial Statements

Regulatory Compliance

Investor Meetings

Analyst Meetings

Financial Statements

Financial Statements

Management Changes

Financial Statements

Pre-Market Approval

Financial Statements, Earni...

Financial Statements

Reorganizations

US FDA Inspection

Procedural Observations

Voluntary action indicated

Certificate under Reg. 74 (...

Virtual Meetings

Analyst Meetings

Product Updates

Asset Acquisitions

Analyst Meetings

Facility Restructuring

Participation in Meet

Investor/Analyst Meet

Equity Investment

Investor Meeting

Analyst/Investor Meet - Int...

Management Changes

Investor Meetings

Participation in Investors ...

Participation in investors ...

In-person meeting

Financial Results

Financial Results Publication

Related Party Transactions

Regulatory Compliance

Observations Received

Compliance Report Submission

Annual Secretarial Compliance

External Links:

Data:

Aurobindo Pharma's Board approved the unaudited financial results for Q2 and half-year ending September 30, 2025, showing a revenue of ₹56,378.9 million compared to ₹52,846.8 million for the previous half-year.

AI Assistant

Aurobindo Pharma Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.